Massachusetts Institute of Technology

National University of Singapore

Kannan Tharakaraman

Ram Sasisekharan

Vidya Subramanian

Venkataramanan Soundararajan

Viswanathan Sasisekharan

S Raguram

Rahul Raman

Luke Nathaniel Robinson

Eng Eong Ooi

Satoru Watanabe

Subhash G Vasudevan

Kuan Rong Chan

Karthik Viswanathan

Akila Jayaraman

Nathan Wilson Stebbins

Eduardo Fleischer

Andrew Peter Hatas

Devin Quinlan

Described herein are mutations in the CH1/CL interface and CH3 constant regions of a bispecific antibody which facilitate heterodimerization and methods for the efficient production of bispecific antibodies. Also disclosed are therapeutic and diagnostic methods for using the antibodies.

Bispecific antibodies having constant region mutations and uses therefor

The present invention provides, among other things, antibody agents (e.g., antibodies, and/or antigen-binding fragments thereof) that bind to DV epitopes, as well as compositions containing them and methods of designing, providing, formulating, using, identifying and/or characterizing them. In some embodiments, provided antibody agents show significant binding to a plurality of DV serotypes. In some embodiments, provided antibody agents show significant binding to all four DV serotypes. Such antibody agents are useful, for example, in the prophylaxis, treatment, diagnosis, and/or study of DV.

Full spectrum anti-dengue antibody

Isolated monoclonal antibodies which bind to Zika virus envelope protein and related antibody-based compositions and molecules are disclosed. Also disclosed are therapeutic and diagnostic methods for using the antibodies.

Antibodies that bind zika virus envelope protein and uses thereof

The present invention provides antibodies (e.g., monoclonal antibodies, human antibodies, humanized antibodies, etc.), which bind to multiple influenza strains. Such antibodies are useful, for example, in the prophylaxis, treatment, diagnosis, and/or study of influenza.

Agents for influenza neutralization

Isolated monoclonal antibodies which bind to Ebola virus glycoprotein and related antibody-based compositions and molecules are disclosed. Also disclosed are therapeutic and diagnostic methods for using the antibodies.

Antibodies that bind Ebola glycoprotein and uses thereof

Antibodies that bind Zika virus envelope protein and uses thereof

The present invention provides, among other things, systems (e.g., comprising compositions and/or methods) for diagnosis, prophylaxis, treatment, prevention, and/or characterization of influenza transmission and/or infection. The present invention also provides methods for monitoring influenza variants for their potential to present a pandemic risk to humans.

Human Adaptation of H7 HA

The present invention provides, among other things, technologies and methodologies for detection, treatment, and/or prevention of influenza transmission and/or infection. The present invention also provides technologies for monitoring influenza variants for their potential to present a pandemic risk to humans.

Human adaptation of H3 influenza

The present invention provides a system for analyzing interactions between glycans and interaction partners that bind to them. The present invention also provides HA polypeptides that bind to umbrella-topology glycans, and reagents and methods relating thereto.

Growing community of inventors

Woburn, MA, United States of America

Kannan Tharakaraman